2014
Book
Vitamin D and Cancer
Description
Vitamin D and Cancer
Authors: Donald L. Trump, Candace S. Johnson, Moray J. Campbell, Edward Giovannucci
Publication Year: 2014
Page Count: 353
This comprehensive volume explores the multifaceted roles of vitamin D in cancer biology, prevention, and therapy. It synthesizes molecular, epidemiological, clinical, and mechanistic research to provide an integrated understanding of how vitamin D metabolism, signaling, and nutritional status influence cancer risk and progression. The book is intended for researchers, clinicians, and healthcare professionals interested in oncology, endocrinology, nutrition, and molecular biology, offering detailed insights into vitamin D’s potential as a chemopreventive and therapeutic agent across a range of malignancies.
Scope and Purpose
The book aims to elucidate the complex biology of vitamin D and its receptor (VDR) in cancer, spanning from molecular mechanisms of vitamin D metabolism and signaling to epidemiological evidence and clinical trial data. It addresses vitamin D’s roles in cellular differentiation, inflammation, angiogenesis, and immune modulation, emphasizing its potential in cancer prevention and treatment. The text also discusses challenges such as vitamin D resistance in tumors, assay standardization, and optimal dosing strategies.
Structure and Major Themes
The book is organized into chapters that systematically cover:
- Vitamin D synthesis, metabolism, and catabolism in relation to cancer causation and therapy.
- The molecular biology of the vitamin D receptor and its transcriptional regulation in cancer cells.
- Anti-inflammatory effects of calcitriol (active vitamin D) in cancer contexts.
- Epidemiological evidence linking vitamin D status with cancer risk and outcomes.
- Vitamin D’s influence on angiogenesis and cardiovascular function relevant to cancer.
- Vitamin D-induced differentiation in various cancer types and mechanisms involved.
- Preclinical and clinical studies on vitamin D as a chemopreventive agent.
- Vitamin D metabolism and skin cancer biology.
- Vitamin D’s role in specific cancers such as prostate, breast, colorectal, and hematologic malignancies.
- Unique enzyme kinetics of vitamin D metabolism and implications for cancer prevention.
- Advances in vitamin D assay methodologies and their clinical relevance.
Vitamin D Synthesis, Metabolism, and Cancer (Chapter 1)
Vitamin D is synthesized in the skin upon UVB exposure and metabolized in the liver and kidney to its active form, 1,25-dihydroxyvitamin D3 (calcitriol). Many tissues, including colon, prostate, and breast, express the enzyme CYP27B1, enabling local extrarenal synthesis of calcitriol, which is critical for regulating cellular proliferation, differentiation, and apoptosis.
Tumor progression often involves dysregulation of vitamin D metabolism enzymes: early cancers may show increased CYP27B1 and decreased CYP24A1 (which degrades calcitriol), but advanced tumors typically exhibit decreased CYP27B1 and increased CYP24A1, leading to vitamin D resistance. Genetic and epigenetic modifications, including DNA methylation and alternative splicing, influence these enzymes’ expression and activity.
Sex hormones modulate vitamin D metabolism; estrogens upregulate CYP27B1 and VDR expression, potentially enhancing vitamin D’s protective effects in colorectal and breast tissues. Nutritional factors such as calcium and phytoestrogens also influence vitamin D metabolism, with calcium intake modulating CYP24A1 and CYP27B1 expression, affecting local calcitriol levels and cancer risk.
The Molecular Cancer Biology of the Vitamin D Receptor (VDR) (Chapter 2)
The VDR is a nuclear receptor that mediates the genomic actions of calcitriol by regulating gene transcription. Upon ligand binding, VDR undergoes conformational changes, heterodimerizes with retinoid X receptor (RXR), and binds vitamin D response elements (VDREs) in target gene promoters. VDR activity is modulated by coactivators and corepressors, post-translational modifications (e.g., phosphorylation), and chromatin remodeling complexes.
VDR signaling is highly cell- and gene-specific, integrating with other transcription factors such as p53 and C/EBPβ. Non-genomic actions of VDR, including membrane-associated signaling, also contribute to its biological effects. In cancer, VDR is rarely mutated but its function can be impaired by altered cofactor expression, epigenetic repression, and oncogenic signaling pathways, leading to resistance.
Mouse models demonstrate VDR’s critical role in calcium homeostasis, bone mineralization, and epithelial tissue maintenance. VDR-null mice develop alopecia, reproductive dysfunction, and increased cancer susceptibility, highlighting VDR’s importance in tissue differentiation and tumor suppression.
Anti-inflammatory Activity of Calcitriol in Cancer (Chapter 3)
Calcitriol exerts potent anti-inflammatory effects that contribute to its anticancer properties, particularly in prostate cancer. It downregulates cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis, and upregulates 15-prostaglandin dehydrogenase, enhancing prostaglandin degradation. Calcitriol also decreases prostaglandin receptor expression, attenuating pro-inflammatory signaling.
Calcitriol induces mitogen-activated protein kinase phosphatase 5 (MKP5), which deactivates p38 MAPK and JNK stress kinases, lowering pro-inflammatory cytokines such as IL-6. It inhibits NF-κB signaling by increasing IκB expression, preventing NF-κB nuclear translocation and suppressing transcription of inflammatory and pro-angiogenic genes.
Combination therapies pairing calcitriol with NSAIDs show synergistic inhibition of prostate cancer cell growth, allowing lower NSAID doses and potentially reducing cardiovascular risks. Clinical trials have explored calcitriol with chemotherapy and NSAIDs, with mixed results, underscoring the need for optimized dosing and patient selection.
Epidemiology of Vitamin D and Cancer Risk (Chapter 4)
Vitamin D status, primarily assessed by circulating 25-hydroxyvitamin D (25(OH)D) levels, is inversely associated with colorectal cancer risk in numerous studies. Higher serum 25(OH)D concentrations correlate with approximately 50% lower colorectal cancer risk compared to deficient levels. Predicted 25(OH)D scores and sun exposure data support these findings.
For prostate cancer, epidemiological evidence is less consistent. Some studies suggest a modest inverse association with advanced disease, while others indicate a U-shaped risk curve or no association. Sun exposure appears more predictive of prostate cancer outcomes than circulating vitamin D levels.
Breast cancer data are mixed, with some studies showing inverse associations with vitamin D intake and sun exposure, particularly in premenopausal women. Other cancers, including pancreatic, ovarian, esophageal, and non-Hodgkin lymphoma, show variable associations, sometimes paradoxical, highlighting the complexity of vitamin D’s role across cancer types.
Randomized controlled trials (RCTs) to date have generally used low vitamin D doses and short durations, limiting their ability to detect protective effects. Ongoing large trials with higher doses and longer follow-up are expected to clarify vitamin D’s preventive potential.
Vitamin D and Angiogenesis (Chapter 5)
Angiogenesis, the formation of new blood vessels, is essential for tumor growth and metastasis. Vitamin D receptor is expressed on endothelial cells and vascular smooth muscle cells (VSMCs). Calcitriol inhibits proliferation and induces apoptosis in tumor-derived endothelial cells, exerting anti-angiogenic effects in cancer models.
Vitamin D’s role is context-dependent: it promotes physiological angiogenesis but inhibits pathological angiogenesis associated with tumors. It modulates VSMC functions relevant to vascular health and disease. These properties support vitamin D’s potential as an adjunct in cancer therapies targeting angiogenesis.
Vitamin D: Cardiovascular Function and Disease (Chapter 6)
Historical perspectives on vitamin D and cardiovascular (CV) disease have evolved from concerns about toxicity to recognition of potential protective effects. Epidemiological studies show inverse associations between serum 25(OH)D levels and CV disease risk and mortality.
Vitamin D influences CV health through modulation of immune and inflammatory responses, endothelial function, matrix metalloproteinases, and insulin resistance. VDR is expressed in heart and vascular tissues, affecting cell proliferation, apoptosis, and vascular tone.
Vitamin D’s biphasic effects on vascular calcification and complex interactions with blood pressure regulation highlight the need for further research. Large RCTs are necessary to confirm vitamin D’s role in CV disease prevention.
Induction of Differentiation in Cancer Cells by Vitamin D (Chapter 7)
Vitamin D induces differentiation in various cancer cells, leading to reduced proliferation and, in some cases, apoptosis. Differentiation therapy aims to revert malignant cells toward a more normal phenotype.
In colon cancer, vitamin D represses Wnt/β-catenin signaling, induces E-cadherin, and upregulates cell cycle inhibitors. Breast cancer cells show differentiation marked by cytoskeletal changes and β-casein production, though responsiveness varies.
Prostate cancer differentiation involves increased prostate-specific antigen (PSA) and modulation of androgen receptor signaling. Keratinocytes and squamous cell carcinoma cells exhibit vitamin D-induced differentiation mediated by calcium signaling and transcription factors, though SCC cells often develop resistance.
In leukemias, vitamin D promotes monocytic differentiation via complex signaling involving MAPKs, PI3K-AKT, and transcription factors like C/EBPβ. Differentiation is accompanied by cell cycle arrest and enhanced survival.
Vitamin D and Cancer Chemoprevention (Chapter 8)
Preclinical studies demonstrate vitamin D’s chemopreventive effects in colorectal, prostate, breast, lung, melanoma, and retinoblastoma models, particularly when administered early. Vitamin D deficiency or VDR knockout increases susceptibility to carcinogenesis.
Clinical trials have yielded mixed results. The Women’s Health Initiative (WHI) trial using 400 IU vitamin D plus calcium showed no significant cancer risk reduction, likely due to low dosing and compliance issues. Other trials with higher doses suggest potential benefits.
Ongoing large-scale prevention trials aim to clarify vitamin D’s role in cancer risk reduction and optimal supplementation strategies.
Molecular Biology of Vitamin D Metabolism and Skin Cancer (Chapter 9)
UVB radiation induces skin cancer via DNA damage but is also essential for cutaneous vitamin D synthesis. Vitamin D metabolism enzymes and VDR are expressed in skin keratinocytes, regulating proliferation and differentiation.
Vitamin D promotes keratinocyte differentiation synergistically with calcium signaling. Squamous cell carcinoma cells often lose responsiveness to vitamin D-induced differentiation due to altered coactivator complexes and oncogenic signaling.
Vitamin D analogs with reduced calcemic effects show promise in skin cancer chemoprevention. Balancing UV exposure to optimize vitamin D synthesis while minimizing skin cancer risk is a public health priority.
Vitamin D and Prostate Cancer (Chapter 10)
Prostate cancer cells express VDR and 1-alpha-hydroxylase but often have reduced local activation of vitamin D, impairing growth inhibition. Vitamin D induces cell cycle arrest, apoptosis, and reduces metastatic potential in preclinical models.
Epidemiological data are mixed, with some studies showing inverse associations between UV exposure and prostate cancer mortality, while vitamin D blood levels show inconsistent correlations. High calcium intake may increase risk by suppressing vitamin D activation.
Clinical trials of calcitriol combined with chemotherapy have shown some promise but also safety concerns, including increased mortality in a phase III trial. Vitamin D analogs with reduced toxicity are under investigation.
Vitamin D and Hematologic Malignancies (Chapter 11)
Vitamin D induces differentiation, growth arrest, and apoptosis in myeloid leukemia cells via VDR-mediated genomic and non-genomic pathways. It modulates hematopoiesis and immune function, enhancing monocyte/macrophage activity and suppressing dendritic cell differentiation.
Clinical trials in myelodysplastic syndrome (MDS) and leukemia have shown limited success, often constrained by hypercalcemia. Combination therapies with agents like ATRA, arsenic trioxide, NSAIDs, and demethylating agents enhance efficacy and reduce toxicity in preclinical models.
Vitamin D analogs with enhanced potency and reduced calcemic effects are being developed, showing promise in vitro and in animal models.
Vitamin D Signaling in Mammary Gland and Breast Cancer (Chapter 12)
Vitamin D status inversely correlates with breast cancer risk. Mammary epithelial cells express VDR and CYP27B1, enabling local activation of vitamin D. VDR signaling regulates proliferation, differentiation, and genome integrity.
VDR knockout mice exhibit increased mammary proliferation and tumor susceptibility. Vitamin D analogs reduce tumor incidence in animal models. Vitamin D resistance in breast cancer involves decreased VDR and increased catabolism via CYP24.
Vitamin D signaling intersects with estrogen receptor pathways and cellular stress responses, influencing tumor suppression.
Vitamin D and Colorectal Cancer (Chapter 13)
Strong epidemiological evidence links higher serum 25(OH)D levels with reduced colorectal cancer risk and adenoma recurrence. Vitamin D receptor and metabolizing enzymes are expressed in colon tissue and tumors.
Serum 25(OH)D measurement methods vary, with newer LC-MS techniques improving specificity. Oral vitamin D supplementation shows biphasic pharmacokinetics, with doses ≥2,000 IU/day needed to achieve protective serum levels.
Clinical trials with low-dose vitamin D have not demonstrated significant prevention, highlighting the need for higher dose studies. Vitamin D deficiency is common in colorectal cancer patients, especially during chemotherapy.
Unique Enzyme Kinetics of the Vitamin D System and Cancer Implications (Chapter 14)
Vitamin D metabolism enzymes exhibit first-order kinetics influenced by substrate (25(OH)D) availability, which fluctuates seasonally. Peripheral tissues adapt slowly to changes in vitamin D supply, potentially leading to transient insufficiency and increased cancer risk during winter months.
Overexpression of CYP24A1 degrades active vitamin D and acts as an oncogene, while CYP27B1 acts as a tumor suppressor. Prostate cancer cells often have reduced CYP27B1 activity, impairing local vitamin D activation.
Large intermittent vitamin D doses may be counterproductive due to enzyme adaptation delays. Steady, moderate dosing is recommended to maintain stable tissue vitamin D levels and reduce cancer risk.
Assessment of Vitamin D Status in the 21st Century (Chapter 15)
Vitamin D measurement has evolved from competitive protein-binding assays to radioimmunoassays, automated chemiluminescent assays, and LC-MS/MS methods. Accurate assessment of 25(OH)D is critical for clinical and research purposes.
Assays vary in specificity, throughput, and ability to distinguish vitamin D2 and D3 forms. LC-MS/MS offers high specificity but is costly and complex. Standardization of assays and calibration to reference ranges are essential to avoid misclassification.
Measurement of active 1,25(OH)2D remains challenging and is reserved for specific clinical indications. Vitamin D status assessment informs cancer epidemiology, prevention strategies, and therapeutic monitoring.
Strengths and Limitations
This book’s strengths lie in its comprehensive, multidisciplinary approach, integrating molecular biology, epidemiology, clinical trials, and assay technology. It provides detailed mechanistic insights alongside practical considerations for vitamin D’s role in cancer prevention and therapy.
Limitations include the evolving nature of vitamin D research, with some clinical trial data still inconclusive and ongoing. The complexity of vitamin D metabolism and signaling, along with variability in assay methods and population differences, necessitates cautious interpretation of findings.
Utility for Cancer-Options Reference Database
This volume serves as an authoritative resource on vitamin D’s multifaceted roles in cancer biology and clinical management. It informs evidence-based discussions on vitamin D supplementation, potential therapeutic applications, and biomarker assessment. The detailed coverage of molecular pathways, epidemiological data, and clinical trials supports informed decision-making for clinicians, researchers, and patients exploring vitamin D-related cancer options.



















































































































